Glenmark Pharmaceuticals Ltd Share Price

Overview

Glenmark Pharmaceuticals Ltd share price is currently ₹2,356.88, down by - ₹21.74 (0.91%) from its previous closing price of ₹2,378.62. The share price has gained 9.59% over the past month and gained 21.9% over the past year. The stock's 52-week low and high are ₹0.00 and ₹2,458.77, respectively. Glenmark Pharmaceuticals Ltd has a market capitalisation of ₹ 65,420.00 Cr. The share price was last updated on 25 Aug 2026, 12:41 PM IST.

Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
GLENMARK
 0.00
- 21.74
0.91%
Healthcare
 0.00(%)1D

Updated: 25 Aug 2026, 12:41:24 pm IST

Market Data

Open Price

 2,343.08

Prev. Close

 2,378.62
 2,328.17

Day Low

 2,374.10

Day High

 0.00

52 Week Low

 2,458.77

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

36.99

Sector PE

42.03

PB Ratio

6.35

Sector PB

5.82

EPS

63.71

Dividend Yield

0.12

Today's Volume

408.214 K

5 Day Avg. Volume

547.298 K

PEG Ratio

1.23

Market Cap.

₹ 65,420.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 250% at ₹2.5/Share
31-Aug-202631-Aug-2026
DividendsInterim Dividend of 250% at ₹2.5/Share
03-Oct-202503-Oct-2025
DividendsFinal Dividend of 250% at ₹2.5/Share
15-Sep-202515-Sep-2025
DividendsFinal Dividend of 250% at ₹2.5/Share
13-Sep-202417-Sep-2024

Mutual Fund Ownership

Mutual Fund Holder
Jun 26
Shares held
Jul 26
Shares held
HDFC Mid Cap Fund - Regular Plan - Growth1.34 Cr
1.34 Cr
no change
Invesco India Midcap Fund - Regular Plan - Growth18.64 Lac
18.64 Lac
no change
Invesco India Contra Fund - Regular Plan - Growth17.02 Lac
17.02 Lac
no change
Kotak Arbitrage Fund - Growth12.46 Lac
13.90 Lac
(11.56%)
Invesco India Large & Mid Cap Fund - Regular Plan - Growth13.43 Lac
13.43 Lac
no change

About Glenmark Pharmaceuticals Ltd 👋

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company's offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.

News & Events

Frequently Asked Questions

What is the share price of Glenmark Pharmaceuticals Ltd?

What is the market cap of Glenmark Pharmaceuticals Ltd?

Should I buy Glenmark Pharmaceuticals Ltd stock now?

What is the 52 week high and low of Glenmark Pharmaceuticals Ltd?

Is the Glenmark Pharmaceuticals Ltd stock good to buy?

Is Glenmark Pharmaceuticals Ltd a good buy for the long term?

Is Glenmark Pharmaceuticals Ltd overvalued or undervalued?

What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?

Start Now